News and media

Teva Canada Limited, headquartered in Toronto, and Teva Canada Innovation, headquartered in Montréal, are part of Teva Pharmaceutical Industries Ltd., the world’s largest generic drug maker. We’re proud to have been part of Canadian healthcare for more than 50 years, to market more than 400 medications across the country and to employ more than 1,000 Canadians.

If you’re looking for information about our company, please contact Public Affairs at Teva Canada Limited at

As the COVID-19 situation evolves globally, we are striving to provide an uninterrupted supply of medicines to the 200 million patients that we serve around the world.

The global emergency surrounding COVID-19 is disrupting the family, work and social lives of many people around the world.

At Teva, we’re working hard to keep the flow of medicines going to patients and healthcare systems. Thousands of colleagues have adapted the way they operate in order to continue performing essential work on our production lines, warehouses and distribution networks.

See how Teva is working to keep medicines moving.

CGPA Releases Blueprint for a Sustainable Supply of Prescription Medicines for Canadians (June 17, 2020)

Teva’s 2019 Environmental, Social and Governance (ESG) Progress Report (June 2020)

Teva Canada Limited is voluntarily recalling TEVA-CARVEDILOL 12.5MG tablets with lot number of 681679 (June 5, 2020)

Teva Canada secures Salbutamol Inhalers from its global supply chain to mitigate shortage in Canadian market (May 19, 2020)

Teva Canada Limited announces the availability of UK-labelled product – Salbutamol Metered Dose Inhaler (MDI) PrSalamol CFC-Free,100 mcg salbutamol per metered dose (May 14, 2020)

Important Safety Information – Importation of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler due to shortage (May 13, 2020)

Teva Canada Limited is voluntarily recalling RATIO-COTRIDIN SYRUP 2L with lot number of 679843 (May 8, 2020)

Teva Canada announces the launch of AJOVYTM for the preventive treatment of migraine in adults who have at least four migraine days per month (April 29, 2020)

Free counselling and coaching for Canadian caregivers during the COVID-19 crisis (April 7, 2020)

Podcast: Pharmacy support for caregivers during the COVID-19 pandemic (April 7, 2020)

Recognizing National Caregiver Day during COVID-19 (April 7, 2020)

COVID-19 is increasing the number of Canadians requiring caregiver information and support. Learn about how to protect yourself and others in the home, as well as those in your community (March 24, 2020)

Teva Canada Economic Impact Report (January 31, 2020)

Teva Canada announces the launch of a bioequivalent generic version of PrGilenya®, PrTeva-Fingolimod Capsules for the treatment of relapsing-remitting multiple sclerosis (MS) (October 31, 2019)

Teva Canada announces the approval of PrHERZUMA® (trastuzumab).  A biosimilar to Herceptin® (September 11, 2019)

View news from Teva around the world

View global media